Focus issueDrug-eluting stents: TAXUS-IV: Editorial CommentSurrogates, substudies, and real clinical end points in trials of drug-eluting stents*
Drug-eluting stents: TAXUS-IV: Editorial Comment
Under an Elsevier user license
open archive
Cited by (0)
- *
Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
- 1
Dr. Kereiakes has a consulting agreement with Advanced Stent Technologies, Conor MedSystems, Inc., Cordis Corporation, and Guidant Corporation.
- 2
Dr. Krucoff has grants/consulting contracts with Boston Scientific Corporation, Inc., Medtronic, Inc., Guidant Corporation, Cordis Corporation, and Johnson & Johnson.
Copyright © 2005 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.